BLACK WEEKSInjektiopullot −15 % · kitit −10 % · muut −5 %koodillaIlmainen toimitus Saksaan alk. €200

Tämä sivu on käännetty automaattisesti, ja siinä voi olla virheitä. Onko suomi äidinkielesi? Otamme mielellämme vastaan palautetta ja korjauksia.Lähetä palautetta

The Peptide Desk The Peptide Desk
Mazdutide, tuotekuva
GLP-1

Mazdutide

GLP-1

  • Lähetetään Saksasta

Tilaus

Kappalehinta - Ilmainen toimitus Saksaan yli 200 €:n tilauksille Black Weeksin aikana
  • DHL seurannalla
  • Huomaamaton pakkaus

4.6/5 Trustpilotissa73 arvostelua

Haettu myös nimellä: Mazdutid · LY3305677 · IBI362

Yhdellä silmäyksellä

Mazdutide lukuina

Tietopankkimme keskeiset luvut.

Koko tietopankkiartikkeli
Class
GLP-1 / glucagon dual agonistoxyntomodulin analogue
Half-life
Several daysweekly dose
Frequency
Once weeklysubcutaneous
Form
Lyophilised powderreconstituted with BAC water
Sizes
5 to 10 mg2 sizes in the shop

Tuotteelle Mazdutide ei ole vielä laboratorioanalyysia. Äänestä sitäTestauta itse, me maksamme puoletKaikki laboratorioanalyysit

Tietoa

Kaikki aiheesta Mazdutide

Tilaa samalla

Mitä tarvitset sen kanssa

Bakteriostaattinen vesi lisätään ostoskoriisi automaattisesti. Ruiskut ja pyyhkeet yhdellä napsautuksella.

Insuliiniruiskut

10 kpl · 5.50 €

Alkoholipyyhkeet

50 kpl · 10 €

Kuinka paljon vettä?

Ruiskun yksiköt injektiopullosi koolle.

Avaa laskuri →

FAQ

Usein kysyttyä

Lähteet jokaiseen vastaukseen: tietopankkiartikkeli

Onko sinulla vielä kysyttävää?

Kirjoita meille, tiimimme auttaa sinua.

Is Mazdutide approved?

In China, yes. The first approval came in June 2025 for long-term weight management in obesity or overweight with a related condition, type 2 diabetes followed in September 2025. Mazdutide is not approved in the EU or the USA, ChEMBL lists phase 3 as the highest phase. The information here describes the state of research and is not a recommendation for use.

How does Mazdutide differ from Tirzepatide and Retatrutide?

The receptors. Mazdutide acts on GLP-1 and glucagon, Tirzepatide on GLP-1 and GIP, Retatrutide on all three. Mazdutide is derived from the gut hormone oxyntomodulin, which naturally addresses both receptors. A running trial with a higher dose compares it directly with Tirzepatide, there are no results yet.

What did the phase 3 trials show?

In GLORY-1 weight fell by 11.0 and 14.0 percent on average after 48 weeks, on placebo it rose by 0.3 percent. In GLORY-2 with a higher dose it was 16.7 versus 1.5 percent after 60 weeks. In type 2 diabetes HbA1c fell by 1.57 and 2.15 percentage points after 24 weeks (placebo 0.14). Against dulaglutide both doses were ahead for HbA1c and weight.

How long does Mazdutide stay in the body?

In the first phase 1b study in China the half-life was between 6.3 and 16.8 days. An attached fatty acid makes this possible. That fits one dose a week, which is how all trials give Mazdutide.

How high were the doses in trials?

The highest study dose was 16 mg per week, in a phase 1 study and a phase 2 trial in the USA. There weight fell by 18.1 percent after 32 weeks, but 20 percent stopped because of side effects. All trials raise the dose in steps over weeks. The entry describes the same principle: start low and only increase while there is no noticeable effect. This is not a dosing recommendation.

Which side effects were seen?

Mainly gastrointestinal effects, mostly mild to moderate. In GLORY-2 53.1 percent had vomiting, 46.9 percent nausea and 39.4 percent diarrhoea (placebo 1.3, 3.2 and 6.5 percent). In GLORY-1 only 0.5 to 1.5 percent stopped because of side effects. In an early study the complaints occurred mainly in the first dose levels.

Which trials are still running?

Four of the listed phase 3 trials are not finished yet: on fatty liver versus semaglutide, on sleep apnoea, in adolescents and on high blood pressure. Phase 2 trials are running on heart failure with obesity and on fatty liver with inflammation (MASH).

Liittyvät

Samankaltaiset tuotteet